

Reimbursement Policy:

Biochemical Markers of Alzheimer Disease and Dementia - Lab Benefit Program (LBM)

POLICY NUMBER	EFFECTIVE DATE:	APPROVED BY
AHS-G2048	3/01/2023	RPC (Reimbursement Policy Committee)

Reimbursement Guideline Disclaimer: We have policies in place that reflect billing or claims payment processes unique to our health plans. Current billing and claims payment policies apply to all our products, unless otherwise noted. We will inform you of new policies or changes in policies through postings to the applicable Reimbursement Policies webpages on emblemhealth.com. Further, we may announce additions and changes in our provider manual and/or provider newsletters which are available online and emailed to those with a current and accurate email address on file. The information presented in this policy is accurate and current as of the date of this publication.

The information provided in our policies is intended to serve only as a general reference resource for services described and is not intended to address every aspect of a reimbursement situation. Other factors affecting reimbursement may supplement, modify or, in some cases, supersede this policy. These factors may include, but are not limited to, legislative mandates, physician or other provider contracts, the member's benefit coverage documents and/or other reimbursement, and medical or drug policies. Finally, this policy may not be implemented the same way on the different electronic claims processing systems in use due to programming or other constraints; however, we strive to minimize these variations.

We follow coding edits that are based on industry sources, including, but not limited to, CPT® guidelines from the American Medical Association, specialty organizations, and CMS including NCCI and MUE. In coding scenarios where there appears to be conflicts between sources, we will apply the edits we determine are appropriate. We use industry-standard claims editing software products when making decisions about appropriate claim editing practices. Upon request, we will provide an explanation of how we handle specific coding issues. If appropriate coding/billing guidelines or current reimbursement policies are not followed, we may deny the claim and/or recoup claim payment.

[POLICY DESCRIPTION](#) | [INDICATIONS AND/OR LIMITATIONS OF COVERAGE](#) | [DEFINITIONS](#) | [SCIENTIFIC BACKGROUND](#) | [GUIDELINES AND RECOMMENDATIONS](#) | [APPLICABLE STATE AND FEDERAL REGULATIONS](#) | [APPLICABLE CPT/HCPCS PROCEDURE CODES](#) | [EVIDENCE-BASED SCIENTIFIC REFERENCES](#) | [REVISION HISTORY](#)

Policy Description:

Alzheimer disease (AD) is a neurodegenerative disease defined by a gradual decline in memory, cognitive functions, gross atrophy of the brain, and accumulation of extracellular amyloid plaques and intracellular neurofibrillary tangles.¹

Indications and/or Limitations of Coverage:

Application of coverage criteria is dependent upon an individual's benefit coverage at the time of the request. Specifications pertaining to Medicare and Medicaid can be found in "Applicable State and Federal Regulations" section of this policy document.

- 1) For individuals with suspected Alzheimer disease or mild cognitive impairment, measurement of the following biomarkers in cerebrospinal fluid **MEETS COVERAGE CRITERIA:**
 - a) Amyloid beta peptides.
 - b) The ratio of total tau (t-tau) to amyloid beta 1-42 (Aβ42).
 - c) The ratio of phosphorylated tau 181 (p-tau181) to Aβ42.
- 2) For individuals with suspected Alzheimer disease or mild cognitive impairment, measurement of the ratio of p-tau 217 (p-tau217) to Aβ42 in plasma using an FDA-approved test (e.g., Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio) **MEETS COVERAGE CRITERIA.**

Reimbursement Policy:

Biochemical Markers of Alzheimer Disease and Dementia - Lab Benefit Program (LBM)

The following does not meet coverage criteria due to a lack of available published scientific literature confirming that the test(s) is/are required and beneficial for the diagnosis and treatment of an individual's illness.

- 3) Measurement of cerebrospinal fluid biomarkers of Alzheimer disease or dementia not mentioned above (e.g., α -synuclein, neural thread proteins) **DOES NOT MEET COVERAGE CRITERIA.**
- 4) Measurement of plasma and/or serum biomarkers of Alzheimer disease or dementia (e.g., p-tau217 or A β 42 as individual markers, total tau protein, amyloid beta 1-40, neural thread proteins, ApoE, ApoE4) **DOES NOT MEET COVERAGE CRITERIA.**
- 5) Measurement of urinary biomarkers of Alzheimer disease or dementia (e.g., neural thread proteins, amyloid beta peptides, urinary extracellular vesicle analysis) **DOES NOT MEET COVERAGE CRITERIA.**
- 6) The use of multianalyte assays, algorithmic analysis, and/or any other tests not mentioned above for the prognosis, diagnosis, and/or management of Alzheimer disease or dementia **DOES NOT MEET COVERAGE CRITERIA.**

Definitions:

Term	Definition
AAN	American Academy of Neurology
AD	Alzheimer disease
AD7c-NTP	Alzheimer-associated neuronal thread protein
ADAD	Autosomal dominant Alzheimer's disease
ALS	Amyotrophic lateral sclerosis
aMCI	Amnesic mild cognitive impairment
APOE	Apolipoprotein E
APOJ	Apolipoprotein J
A β 40	Amyloid Beta 40
A β 42	Amyloid Beta 42
AUC	Area under the curve
A β 25-35	B-amyloid 25-35
CCCDTD	Canadian Consensus Conference on the Diagnosis and Treatment of Dementia
CDC	Centers For Disease Control and Prevention
CLIA '88	Clinical Laboratory Improvement Amendments Of 1988
CMS	Centers For Medicare and Medicaid
CN	Cognitively normal
CNT	Carbon nanotubes
CSF	Cerebrospinal fluid

Reimbursement Policy:

Biochemical Markers of Alzheimer Disease and Dementia - Lab Benefit Program (LBM)

Term	Definition
CT	Computerized tomography
CU	Cognitively unimpaired
DLB	Dementia with lewy bodies
EFNS	European Federation of Neurological Societies
EV	Extracellular vesicle
FDA	Food And Drug Administration
FDG	Fluoro-deoxyglucose
GBSC	Global Biomarker Standardization Consortium
GSEA	gene set analysis
HD	Huntington disease
IWG	International Working Group
JPND	Joint Program—Neurodegenerative Disease Research
LDT	Laboratory-developed test
LP	Lumbar puncture
MCI	Mild cognitive impairment
MRI	Magnetic resonance imaging
NFH	Heavy chain
NFL	Neurofilament light chain
NG	Neurogranin
NIA	National Institute on Aging
NICE	National Institute for Health and Care Excellence
NINCDS	National Institute of Neurological and Communicative Disorders and Stroke
NrCAM	Neuronal cell adhesion molecule
NTP	Neuronal thread protein
PD	Parkinson disease
PET	Positron emission tomography
PKCe	Protein kinase c-epsilon
p-tau	Phosphorylated tau
PTP	Pancreatic thread protein
REM	Rapid eye movement
SCD	Subjective cognitive decline

Reimbursement Policy:

Biochemical Markers of Alzheimer Disease and Dementia - Lab Benefit Program (LBM)

Term	Definition
sCJD	Sporadic Creutzfeldt–Jakob disease
SNAP23	Synaptosomal-associated protein 23
SNMMI	Society of Nuclear Medicine and Molecular Imaging
SORL	Sortilin-related receptor
t-tau	Total tau
USPSTF	United States Preventive Services Task Force

Scientific Background:

Alzheimer disease (AD) is a devastating neurodegenerative disease with a strong genetic component and is the predominant form of dementia (60–70%). In 2021, 57 million people worldwide were living with dementia and it is the seventh leading cause of death and globally is one of the major causes of disability and dependency among older individuals.² The average lifetime risk of developing AD is 10–12%; this risk at least doubles with the presence of a first-degree relative with the disorder.³ The genetic predisposition of AD, even for late-onset AD patients, is estimated to be 60–80%.⁴ According to the Centers for Disease Control and Prevention (CDC), the total adjusted death rates in the U.S. varied according to ethnicity with white, non-Hispanics having a rate of 70.8 per 100,000 individuals as compared to 65.0 and 46.0 per 100,000 for non-Hispanic black and Hispanic individuals.⁵

Most patients develop clinical symptoms at or after the age of 65 (spontaneous or late-onset AD), however 2–10% of patients have an earlier onset of disease (early-onset AD).⁶ AD is characterized by severe neuronal loss, aggregation of extracellular amyloid β plaques, and intraneuronal tau protein tangles, resulting in progressive deterioration of memory and cognitive functions and ultimately requiring full-time medical care.⁷ There is an enormous burden on public health due to the high costs associated with care and treatment. Aside from drugs that temporarily relieve symptoms, no treatment exists for AD.⁸

Many genetic studies have recently identified that late-onset Alzheimer disease is associated with the apolipoprotein E (*APOE*), apolipoprotein J (*APOJ*), and sortilin-related receptor (*SORL*) genes mainly expressed by various types of glial cells such as microglia, oligodendrocytes, and astrocytes; this has helped AD-related research stray from neurons and toward glial cells and neuroinflammation.⁹

The pathological processes of AD and other degenerative dementias are likely well underway before clinical symptoms manifest, therefore, biomarkers may have potential utility in the early diagnosis of dementia.¹⁰ Mild cognitive impairment (MCI) is an intermediate state between normal cognition and dementia, recognizable as an early manifestation of dementia. MCI due to AD is the most common type of MCI.¹¹

Studies have examined the use of cerebrospinal fluid (CSF) markers for predicting conversion from MCI to dementia. The most replicated CSF biomarkers include tau protein or phosphorylated tau protein and amyloid beta 42 (A β 42) peptide, which may be represented by a low ratio of A β 42 to A β 40 levels, or a low ratio of A β 42 to tau levels. However, these tests vary in sensitivity (36 to 100 percent) and specificity (29 to 91 percent), and in the types of assays used. Recent research notes that the A β 42/40 ratio should be used over the measurement of A β 42 alone, as this ratio gives a more accurate diagnosis when analyzing CSF AD biomarkers.¹² Currently, these markers are of marginal clinical utility and do not have an established role in the evaluation of patients in the clinical setting.^{10,13}

Reimbursement Policy:

Biochemical Markers of Alzheimer Disease and Dementia - Lab Benefit Program (LBM)

Other biomarkers in CSF such as cargo proteins (e.g. chromogranin-B, α -synuclein), carnosinase I, chromogranin A, and NrCAM (neuronal cell adhesion molecule) have been proposed to provide clinical value for assessment of AD. Levels of each of the above CSF proteins are found to be statistically different among clinically defined patient groups with different degrees of cognitive impairment. However, the absence of a clinical treatment makes this relatively invasive test of questionable clinical utility.^{13,14}

Plasma levels of the E4 variant of apolipoprotein E (ApoE4) may be a less invasive option for diagnosing patients. *ApoE* facilitates the delivery of cholesterol and promotes neuronal functionality and decreased apoE4 levels associated with neuronal degradation are suggestive of AD.¹⁵ However, results are inconsistent across various studies. The correlation between altered levels of *ApoE* and ApoE4 with AD pathology is still not definitive, and standardization of methods is needed.¹⁴

Studies have been conducted comparing the telomere length of peripheral blood leukocytes with those in the cerebellum.¹⁶ The shortening of telomere length is indicative of chronic stress on the human body, common in AD patients. However, cerebellar telomere length is not considered a diagnostic tool to evaluate the risk of inherited AD.¹⁶ Moreover, many other diseases also contain pathologies that induce stress on the body, so results may be confounded with other underlying health problems.¹⁴

High concentrations of neuronal thread protein (NTP), specifically AD-associated NTP (AD7c-NTP), in urine is found to be representative of AD pathology.¹⁶ NTP is a brain protein that interacts with antibodies produced against pancreatic thread protein (PTP), a protein that contains structural components highly similar to the fibrils found in neuronal plaques in AD patients.^{16,17} Moreover, AD7c-NTP is reflective of neuronal cell dysfunction. Unfortunately, NTP is more useful in determining the progression of the disease in patients who already have AD and not for early diagnosis.^{14,18}

Studies have also identified a potential relationship between nanoscale extracellular vesicles (exosomes) and AD. Researchers note that exosomes may be an important factor in the progression of AD pathogenesis, but first need to identify the underlying AD-related mechanisms.¹⁹

Other media, such as saliva, have been proposed to provide diagnostic information for AD. A total of 6,230 metabolites from saliva were tested, and three were found to differentiate between MCI, AD, and cognitively normal patients.²⁰

None of these tests or biomarkers are valid as a stand-alone diagnostic test. The lack of standardized techniques makes diagnostic accuracy across all scenarios difficult to achieve. Current AD diagnostic standards using evaluation of clinical presentation have maintained a high level of accuracy, combined with the lack of a clinical treatment make all early AD diagnostic tests and biomarkers of limited clinical utility.^{14,21} However, research criteria have incorporated both molecular and topographic biomarker data into the research definitions of both symptomatic and pre-symptomatic forms of AD, anticipating that once biomarkers become more standardized, they will be incorporated into clinical diagnostic algorithms for AD.^{13,22}

Proprietary Testing

Proprietary tests exist for assessment of AD biomarkers. C2N Diagnostics offers PrecivityAD™, a blood test that measures the ratio of A β 42 to A β 40 and ApoE detection. C2N Diagnostics received a “Breakthrough Device Designation” from the FDA in January 2019 for their test measuring the ratio of A β 42 to A β 40.²³ Fujirebio Diagnostics offers the *in vitro* Lumipulse® G β -Amyloid Ratio (1-42/1-40) test, which combines the results of the Lumipulse® G β -Amyloid 1-42 and Lumipulse® G β -Amyloid 1-40 to create a ratio of beta-amyloid 1-42 and beta-amyloid 1-40 concentrations in CSF with the LUMIPULSE G1200 system.²⁴ This is intended to predict the likelihood of amyloid plaque formation in potential AD. This assay received the “Breakthrough Device Designation” from the FDA in May 2022.²⁵

Reimbursement Policy:

Biochemical Markers of Alzheimer Disease and Dementia - Lab Benefit Program (LBM)

Roche Diagnostics received 501(k) clearance from the FDA in 2022 for their Elecsys® beta-Amyloid (1-42) CSF II (Abeta42) and Elecsys® Phospho-Tau (181P) CSF (pTau181) assays in 2022 for adults 55 years and older who are evaluated for the disease and other cognitive impairments to generate a pTau181/Abeta42 ratio value. The company cites that these assays “achieve 90% concordance with the Amyloid PET scan imaging and have the potential to provide a more affordable and accessible routine option to confirm the presence of amyloid in the brain.” They can also detect pathology in earlier stages of disease due to the correlative changes in biomarkers.²⁶ In June 2023, Roche Diagnostics also received 501(k) clearance from the FDA for the Elecsys® beta-Amyloid (1-42) CSF II (Abeta42) and Elecsys® Total-Tau CSF assays (tTau) in the same population through the tTau/Abeta42 ratio, and will be available in Q4 2023. The company endorses that these assays provide a cost-effective, more widely available alternative to the recommended PET imaging option with minimal radiation exposure. The ratio would be “consistent with a negative amyloid PET scan if the result is less than or equal to the cutoff (negative), and with a positive amyloid PET scan if the result is above the ratio cutoff (positive).”²⁷

On July 6, 2023, Quanterix® launched the LucentAD test, which measures serum levels of tau protein phosphorylated at Thr181 (p-Tau 181), which is a marker of AD pathology. It is intended to assist in the diagnostic evaluation of AD with other tools, but clues providers into a patient's likelihood of amyloid-related pathology. It is not currently approved by the FDA, but has been studied in conjunction with the drug lecanemab in its effectiveness for treating AD therapy response.²⁸

Lecanemab is an antibody intravenous (IV) infusion therapy. It works by targeting and removing beta-amyloid from the brain. It has received traditional approval from the U.S. Food and Drug Administration (FDA) to “treat early Alzheimer's disease, including people living with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease who have confirmation of elevated beta-amyloid in the brain.”²⁹ Lecanemab lowers beta-amyloid in the brain, reducing cognitive and functional decline in people living with early Alzheimer's. This treatment is appropriate for people with early Alzheimer's who have been confirmed to have elevated beta-amyloid levels. The test is appropriate in those with elevated beta-amyloid levels and as such, before treatment could be considered, the physician would first need to confirm the presence of beta-amyloid plaques. Currently, the FDA does not specify a diagnostic tool to determine elevated beta-amyloid. However, some examples of tools to diagnose beta-amyloid elevation include PET scan or lumbar puncture (CSF) tests.²⁹

The Syn-One Test offered by CND Life Sciences is intended to aid in the diagnosis of synucleinopathies, which includes Parkinson Disease (PD), dementia with Lewy bodies, multiple system atrophy, and pure autonomic failure. Using a skin biopsy, the test detects (through immunostaining) abnormal (phosphorylated) alpha-synuclein (P-Syn) in skin nerve fibers. The Syn-One pathology report also includes results for small fiber neuropathy and amyloidosis.³⁰

There is a growing body of evidence confirming the association of P-Syn with various synucleinopathies and P-Syn's potential utility as a diagnostic biomarker. Donadio, et al. (2019) reported “excellent” inter- and intra-laboratory reproducibility when using the skin biopsy technique to assay for P-Syn, providing increased confidence that this approach may be feasible across institutions. Levine, et al. (2021) showed that P-Syn might be useful as a marker for other disease states (postural orthostatic tachycardia syndrome), expanding the potential applications of the analyte for different clinical scenarios.

Despite the growing support, other studies have highlighted some concerns: Kim, et al. (2019) reviewed the available data regarding the use of cutaneous alpha-synuclein as a marker for synucleinopathies and confirmed that a high specificity is consistently reported across studies, but that sensitivity measurements can vary widely. The authors suggest that this is likely influenced by the specific type of disease, as well as differences in design and methodology (i.e., biopsy site, tissue thickness, or fixation methods). Waqar, et al. (2023) published a similar review that emphasized the variability in reported sensitivity of P-Syn detection from skin biopsies, as well as the small sample sizes in many of the published studies to date. The authors do acknowledge, however, the many advantages of using skin samples, including the low cost and high patient tolerance of the technique.

Reimbursement Policy:

Biochemical Markers of Alzheimer Disease and Dementia - Lab Benefit Program (LBM)

Clinical Utility and Validity

Dage, et al. (2016) studied the correlation of tau protein levels (in plasma) with neuronal damage. A total of 378 cognitively normal (CN) patients were examined, along with 161 patients with mild cognitive impairment (MCI). Baseline plasma tau protein levels were measured. The authors found that plasma tau levels were higher in MCI patients compared to CN patients (4.34 pg/mL for MCI compared to 41.4 pg/mL for CN, $p = .078$). The authors also performed a regression accounting for age, gender, education, and ApoE, which suggested that higher plasma tau levels were associated with worse memory loss and abnormal cortical thickness.³⁵

Lewczuk, et al. (2017) compared the ratio of A β 42/40 to just A β 42 as measurements of clinical AD. A total of 200 patients (150 PET-negative, 50 PET-positive for amyloid) were examined and compared to the positron emission tomography (PET) results. The authors found that the ratio of A β 42/40 agreed more strongly with the PET results (89.4% concordance compared to 74.9% concordance for A β 42 only). A larger area under the curve was found for the A β 42/40 measurement compared to just A β 42 (0.936 compared to 0.814). The authors concluded that “the CSF A β 42/40 ratio is superior to A β 42 alone as a marker of amyloid-positivity by PET.”³⁶

Talwar, et al. (2016) performed a meta-analysis on CSF ApoE levels in AD patients. Twenty-four studies, including 1064 AD cases and 1338 healthy controls, were reviewed. The authors found that although the total sample did not indicate a significant association between AD and ApoE levels, a subgroup analysis controlling for sample size ($n > 43$) indicated significantly lower ApoE levels in AD patients compared to controls. The authors considered CSF ApoE levels to have “potential” as an indicator of AD association.³⁷

Wang, et al. (2018) evaluated the clinical value of α -synuclein in MCI and AD. The investigators added α -synuclein and phosphorylated α -synuclein to a biomarker panel containing A β 42, tau, and phosphorylated tau and evaluated the new panel’s performance. A total of 729 CSF samples were taken. The phosphorylated version of α -synuclein was found to weakly associate with diagnosis at baseline, but total α -synuclein was not. CSF α -synuclein was found to predict the Alzheimer Disease Assessment Scale-Cognitive, memory, executive function, and progression from MCI to AD. Longitudinal biomarker changes were not found to differ between groups. Overall, α -synuclein was found to potentially better predict AD changes better than the classic biomarkers.³⁸

Zhang, et al. (2014) performed a meta-analysis focusing on urinary Alzheimer-associated neuronal thread protein (AD7c-NTP)’s diagnostic ability for AD. Nine studies were reviewed for probable and possible AD, and the authors evaluated AD7c-NTP’s sensitivity at 0.87, specificity at 0.89, positive likelihood ratio at 8.13, and negative likelihood ratio at 0.15.³⁹

Wang, et al. (2019) explored the potential of urinary extracellular vesicle (EV) biomarkers in neurological disorders, including AD, Parkinson Disease (PD), and Huntington Disease (HD). A discovery cohort of 50 individuals was used to create the initial set of EV proteins and a set of 108 individuals was used to further develop the list of biomarkers. The authors identified “hundreds” of commonly expressed EV proteins with stable expression. SNAP23 and calbindin were most elevated in PD cases, with an 86% prediction of diagnostic success in the discovery cohort and 76% prediction of diagnostic success in the replication cohort. Moreover, “Broad Gene set analysis (GSEA) further reveals a prominent link to Alzheimer disease with 10.4% of the genes known to be down-regulated in the brains from patients with Alzheimer disease identified in urinary EVs.”⁴⁰

Liu, et al. (2018) examined the urinary metabolic profile of β -amyloid 25-35 (A β 25-35)-injected rats. This was intended to establish AD in the rats, allowing the impairment of spatial learning and memory to be tested in the rats after eight weeks. The authors identified the characteristic AD symptoms after eight weeks (cognitive dysfunction, hippocampus damage, A β formation and tau phosphorylation) as well as 45 altered metabolites involving eight metabolic pathways. The investigators concluded that “pathogenesis of AD was mainly due to gut microbiome dysbiosis, inhibition of energy metabolism, oxidative stress injury and loss of neuronal protective substances.”⁴¹

Reimbursement Policy:

Biochemical Markers of Alzheimer Disease and Dementia - Lab Benefit Program (LBM)

Fossati, et al. (2019) studied the correlation of plasma tau with cerebrospinal fluid (CSF) tau and phosphorylated tau (P-tau). A total of 97 subjects were included (68 healthy controls and 29 AD patients). Plasma tau was found to be higher in AD patients compared to healthy controls (area under curve: 0.79). However, CSF tau and plasma tau were “poorly” correlated. The addition of plasma tau to the receiver operating curve of CSF tau increased the area under curve to 0.82 from 0.80 and increased the curve of P-tau to 0.88 from 0.87. The authors concluded that “adding plasma tau to CSF tau or P-tau improves diagnostic accuracy, suggesting that plasma tau may represent a useful biomarker for AD.”⁴²

Tatebe, et al. (2017) developed an immunoassay to quantify plasma p-tau181. Three cohorts were used to validate the assay. In the first cohort (20 AD patients, 15 controls), the tau levels were found to be higher in the AD patients (0.171 ± 0.166 pg/ml in AD versus 0.0405 ± 0.0756 pg/ml in controls). In the second cohort (20 Down Syndrome patients, 22 controls), the tau levels were higher in the Down Syndrome patients (0.767 ± 1.26 pg/ml in DS versus 0.0415 ± 0.0710 pg/ml in controls). Finally, in the third cohort (eight AD patients, three other neurological diseases), the tau levels were found to correlate well with the CSF tau levels ($r^2 = 0.4525$). Overall, the authors suggested that “that the plasma p-tau181 is a promising blood biomarker for brain AD pathology.”⁴³

Shen, et al. (2019) completed a meta-analysis review of 170 studies to research the role of inflammatory markers in AD and MCI. Increased periphery levels, compared to controls, were found with many types of biomarkers including high-sensitivity C reactive protein, $p < 0.05$; interleukin-6, $p < 0.005$; soluble tumour necrosis factor receptor 1, $p < 0.005$; soluble tumour necrosis factor receptor 2, $p < 0.005$; alpha1-antichymotrypsin, $p < 0.005$; IL-1 β , $p < 0.05$; soluble CD40 ligand, $p < 0.05$; CSF levels of IL-10, $p < 0.05$; monocyte chemoattractant protein-1, $p < 0.005$; transforming growth factor-beta 1, $p < 0.05$; soluble triggering receptor expressed on myeloid cells2, $p < 0.001$; YKL-40, $p < 0.001$; α 1-ACT, $p < 0.001$; nerve growth factor, $p < 0.005$; and visinin-like protein-1, $p < 0.005$.⁴⁴ The authors conclude that all the significant relationships found in this large meta-analysis help to support “the notion that AD and MCI are accompanied by inflammatory responses in both the periphery and CSF.”⁴⁴

Palmqvist, et al. (2019) analyzed two different, cross-sectional, multicenter studies ($n=1079$). The CSF A β 42/A β 40 ratio was used to identify AD via Elecsys immunoassays from Roche Diagnostics; further, plasma neurofilament light chain (NFL), heavy chain (NFH), and APOE genotype were also analyzed in the first cohort of patients ($n=842$). “In cohort 1, plasma A β 42 and A β 40 predicted A β status with an area under the receiver operating characteristic curve (AUC) of 0.80 (95% CI, 0.77-0.83). When adding APOE, the AUC increased significantly to 0.85 (95% CI, 0.82-0.88).”⁴⁵ Cohort 2 had similar results with a slightly higher AUC (0.86; 95% CI, 0.81-0.91). The authors conclude by stating that “Plasma A β 42 and A β 40 measured using Elecsys immunoassays predict A β status in all stages of AD with similar accuracy in a validation cohort. Their accuracy can be further increased by analyzing APOE genotype.”⁴⁵

Kim, et al. (2020) studied the diagnostic utility of multiplexed sensing to detect multiple AD biomarkers (t-tau, p-tau181, A β 42, and A β 40) in human plasma using densely aligned carbon nanotubes (CNT). The CNT sensor assay exhibited superior sensitivity and precision, enabling the platform to accurately quantify AD biomarkers despite the hundreds of other agents in the blood plasma. The densely aligned CNT sensor array was $10-10^3$ times more sensitive than the commercially available sandwich-type or enzyme-linked immunosorbent assay. The authors conclude that “by measuring the levels of t-tau/A β 42, p-tau181/A β 42, and A β 42/A β 40 in clinical blood samples, the sensor array successfully discriminates the clinically diagnosed AD patients from healthy controls with an average sensitivity of 90.0%, a selectivity of 90.0%, and an average accuracy of 88.6%.”⁴⁶

Simrén, et al. (2021) studied the diagnostic and prognostic potential of plasma biomarkers in Alzheimer disease. Various biomarkers, including phosphorylated-tau181 (P-tau181), neurofilament light, amyloid- β (A β 42/40), total-tau and glial fibrillary acidic protein, were analyzed in 99 cognitively unimpaired (CU) patients, 107 mild cognitive impairment (MCI) patients, and 103 Alzheimer disease (AD) patients. According to the results, P-tau181 significantly outperformed all biomarkers in differentiating AD dementia from CU. Higher P-tau181 value was associated with increased cognitive decline and gray matter loss in temporal regions. The authors conclude that “these findings highlight the potential value of plasma P-tau181 as a non-invasive and cost-effective diagnostic and prognostic biomarker in AD.”⁴⁷

Reimbursement Policy:

Biochemical Markers of Alzheimer Disease and Dementia - Lab Benefit Program (LBM)

Qu, et al. (2021) performed a systematic review and meta-analysis of 150 studies aiming to evaluate the effect of AD biomarkers on blood. The authors performed a “random-effects meta-analysis based on the ratio of means method and multivariable-adjusted effect estimates.” The results demonstrated that T-tau, P-tau and NfL increased, and that AβPPR decreased from controls to amnesic MCI (aMIC) to AD. Aβ42, Aβ42/40, and P-tau217 all had valid diagnostic accuracy. The authors conclude that the significant changes in core blood biomarkers support that “biomarkers were strongly valid in identifying AD.”⁴⁸

Chen, et al. (2021) performed a meta-analysis of 17 studies aimed at calculating the diagnostic accuracy of blood-based biomarkers. The authors compared the diagnostic odds ratio (DOR) of biomarkers between controls, AD, and aMIC conditions. When comparing AD and control groups, the plasma Aβ42 DOR was 32.2 (sensitivity = 88 %, specificity = 81 %), the plasma Aβ oligomer DOR was 29.1 (sensitivity = 80 %, specificity = 88 %), and the plasma tau DOR was 52.1 (sensitivity = 90 %, specificity = 87 %). When comparing aMIC and controls, the plasma Aβ42 DOR was 60.4 (sensitivity = 86 %, specificity = 90 %), and the plasma tau DOR was 49.1 (sensitivity = 79 %, specificity = 94 %). The authors conclude that blood-based biomarkers are “minimally invasive and cost-effective tools for detecting AD; however, the evidence for detecting aMIC was still limited.”⁴⁹

Yoong, et al. (2021) performed a systematic review and meta-analysis of 13 studies aiming to address the prognostic utility of a new CSF biomarker: Neurogranin (Ng). Core CSF biomarkers such as Aβ42, T-tau, and P-tau can support AD diagnosis, but cannot predict AD progression. Ng has been shown to predict cognitive decline. The authors found evidence that CSF Ng can predict Mini-Mental State Examination (MMSE) decline in Aβ⁺ MCI patients and the decline of memory and executive function in MCI. Additionally, CSF Ng/Aβ42 was also found likely to predict cognitive decline. The authors conclude that CSF Ng may be an applicable AD biomarker, but more studies are required to validate its use.⁵⁰

Nojima, et al. (2022) investigated the clinical utility of measuring CSF biomarkers through the LUMIPULSE® system in correlation with Aβ deposition status confirmed by amyloid PET. From 199 CSF samples from patients with confirmed AD and underwent amyloid PET, measurements of Aβ 1–40 (Aβ40), Aβ 1–42 (Aβ42), total tau (t-Tau), and phosphorylated tau-181 (p-Tau181) using the LUMIPULSE system were taken and analyzed with a multivariable logistic regression model. Through this, they were able to determine that there was diagnostic agreement between the biomarker levels and amyloid PET imaging, and that there was statistical significance in the association between amyloid PET status and Aβ40 and Aβ42, with the ratios providing better diagnostic agreement than single biomarkers alone. Researchers also determined that the statistically significant correlation between the Aβ42/Aβ40 ratio and p-Tau181 may render a plausible utility in predicting brain Aβ pathology. The CSF findings may also potentially draw parallels to benefits with measuring blood plasma levels of the AD biomarkers with high-sensitivity assays, but the “plasma biomarker levels could be affected by small measurement variations caused by preanalytical handling and analytical performance, leading to misclassification (i.e., false-negative or false-positive for Aβ pathology).”⁵¹

Schindler, et al. (2024) compared commercial blood tests for AD. The study included 1,179 plasma samples, from 393 participants, which had been tested with C2N Diagnostics PrecivityAD2, Fujirebio Diagnostics Lumipulse, ALZpath Quanterix, Janssen LucentAD Quanterix, and Roche Diagnostics NeuroToolKit assays. “The major finding of this study was that regardless of the specific assay, plasma p-tau217 had the highest classification accuracies and correlations with all key outcomes studied—amyloid PET, tau PET, cortical thickness, and cognitive impairment.”⁵²

Reimbursement Policy:

Biochemical Markers of Alzheimer Disease and Dementia - Lab Benefit Program (LBM)

Guidelines and Recommendations:

National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) and the Alzheimer's Disease and Related Disorders Association (ADRDA)

In 1984, the NINCDS and ADRDA developed clinical criteria for the diagnosis of AD. While evidence to date has used NINCDS/ADRDA's AD classification, in 2011, the National Institute on Aging and the Alzheimer's Association workgroup revised diagnostic criteria for diagnosis of dementia due to Alzheimer's disease.⁵³

The biomarkers reviewed in this policy are included in a category among revisions to AD diagnostic criteria- "probable AD dementia with evidence of the AD pathophysiological process." However, the diagnostic criteria workgroup publication noted "we do not advocate the use of AD biomarker tests for routine diagnostic purposes at the present time. There are several reasons for this limitation: 1) the core clinical criteria provide very good diagnostic accuracy and utility in most patients; 2) more research needs to be done to ensure that criteria that include the use of biomarkers have been appropriately designed, 3) there is limited standardization of biomarkers from one locale to another, and 4) access to biomarkers is limited to varying degrees in community settings. Presently, the use of biomarkers to enhance certainty of AD pathophysiological process may be useful in three circumstances: investigational studies, clinical trials, and as optional clinical tools for use where available and when deemed appropriate by the clinician."⁵³

Alzheimer's Association

The Alzheimer's Association has initiated a quality control program for CSF markers, noting that "Measurements of CSF AD biomarkers show large between laboratory variability, likely caused by factors related to analytical procedures and the analytical kits. Standardization of laboratory procedures and efforts by kit vendors to increase kit performance might lower variability, and will likely increase the usefulness of CSF AD biomarkers."⁵⁴

In 2013, the Alzheimer's Association published recommendations for operationalizing the detection of cognitive impairment in the primary care setting.⁵⁵ It stated that "the use of biomarkers (e.g., CSF tau and beta amyloid proteins, amyloid tracer positron emission tomography scans) was not considered as these measures are not currently approved or widely available for clinical use."

In 2018, a multidisciplinary group of the Alzheimer's Association published criteria for lumbar puncture and CSF testing in the diagnosis of AD. The committee recommends CSF biomarker testing for six clinical indications deemed appropriate, as listed in the table below.

Table 1: Clinical indications for appropriate use of LP and cerebrospinal fluid testing in the diagnosis of AD.⁵⁶

No.	Indication	Ratings
1	Cognitively unimpaired and within normal range functioning for age as established by objective testing; no conditions suggesting high risk and no SCD [subjective cognitive decline] or expressed concern about developing AD	Inappropriate
2	Cognitively unimpaired patient based on objective testing, but considered by patient, family informant, and/or clinician to be at risk for AD based on family history	Inappropriate

Reimbursement Policy:

Biochemical Markers of Alzheimer Disease and Dementia - Lab Benefit Program (LBM)

No.	Indication	Ratings
3	Patients with SCD (cognitively unimpaired based on objective testing) who are considered to be at increased risk for AD	Appropriate
4	Patients with SCD (cognitively unimpaired based on objective testing) who are not considered to be at increased risk for AD	Inappropriate
5	MCI that is persistent, progressing, and unexplained	Appropriate
6	Patients with symptoms that suggest possible AD	Appropriate
7	MCI or dementia with an onset at an early age (<65)	Appropriate
8	Meeting core clinical criteria for probable AD with typical age of onset	Appropriate
9	Symptoms of REM sleep behavior disorder	Inappropriate
10	Patients whose dominant symptom is a change in behavior (e.g., Capgras Syndrome, paranoid delusions, unexplained delirium, combative symptoms, and depression) and where AD diagnosis is being considered	Appropriate
11	Use to determine disease severity in patients having already received a diagnosis of AD	Inappropriate
12	Individuals who are apolipoprotein E (APOE) ε4 carriers with no cognitive impairment	Inappropriate
13	Use of LP in lieu of genotyping for suspected ADAD mutation carriers	Inappropriate
14	ADAD mutation carriers, with or without symptoms	Inappropriate

Abbreviations: AD, Alzheimer's disease; LP, lumbar puncture; REM, rapid eye movement; SCD, subjective cognitive decline; ADAD, autosomal dominant Alzheimer's disease; MCI, mild cognitive impairment.

The workgroup has also identified several gray areas where more research is needed. The authors note that "One question that will need further data is whether measuring a ratio of CSF Aβ42/40 yields better diagnostic performance than measuring Aβ42 alone. Another question is how to characterize neurodegeneration using CSF biomarkers, and whether neurodegeneration in the absence of positive amyloid biomarkers predicts progression in persons with MCI."⁵⁶ Further, the authors also state that "much more work is needed to document the potential impact of CSF AD biomarker testing on clinical outcomes in patients across the spectrum of AD."⁵⁶

In 2022, the Alzheimer's Association published a recommendation on the appropriate use of blood-based biomarkers (BBMs) in AD. In this recommendation, they note that BBMs are showing promise in revolutionizing the diagnostic and prognostic work-up of AD. However, they still caution that BBMs should not yet be used as primary endpoints in pivotal trials. The recommend that BBMS may be cautiously used in specialized memory clinics, but additional data are needed before BBMS can be used as a stand-alone diagnostic AD marker or before they should be considered for use in primary care. While they do recognize that BBMs are useful as (pre)-screeners for clinical trials, they only cautiously recommend the use of BBMs outside the clinical trial setting:

Reimbursement Policy:

Biochemical Markers of Alzheimer Disease and Dementia - Lab Benefit Program (LBM)

“Recommendations of the use of AD-associated BBMs in clinical trials and practice:

Use of BBMs in specialized memory clinic settings:

(5) BBMs (with established thresholds) should currently only be used in symptomatic patients at specialist clinics and the results should be confirmed whenever possible with CSF or PET. Additional data are needed before use of BBMs as stand-alone diagnostic markers.

Use of BBMs in primary care:

(6) Additional data are needed for use of BBMs in primary care.”⁵⁷

“That said, the implementation of such markers in trials and practice must be done in a careful and controlled way not to accidentally cause more harm than good. Much more research is therefore needed before widespread clinical use of BBMs as we have outlined above. Such research is also needed before the community can establish Appropriate Use Criteria for clinical use of BBMs, which is a prerequisite for general use of such markers in the clinic. However, the acquired experience from implementation of CSF AD biomarkers and A β -PET in many countries will ensure rapid validation of relevant BBMs in the first contexts of use, including trials and specialized memory clinics. The implementation of BBMs in primary care will likely take much longer, because relevant and high-quality research studies on AD-related BBMs in this setting are very few, but hopefully more prospective studies will be launched in the coming years using relevant and accurate reference standards.”⁵⁷

In 2024, the Alzheimer’s Association updated their recommendations for the diagnosis and staging of AD. The update works to define AD biologically by including biomarkers and objective criteria, shifting away from diagnosis based on syndromic presentation. “We define Alzheimer’s disease (AD) to be a biological process that begins with the appearance of AD neuropathologic change (ADNPC) while people are asymptomatic. Progression of the neuropathologic burden leads to the later appearance and progression of clinical symptoms.” “AD is defined by its unique neuropathologic findings; therefore, detection of AD neuropathologic change by biomarkers is equivalent to diagnosing the disease.”⁵⁸

The 2024 guideline includes the definition of Core 1 and Core 2 biomarkers. Core 1 biomarkers “become abnormal around the same time as amyloid PET” and “an abnormal Core 1 biomarker result is sufficient to establish a diagnosis of AD and to inform clinical decision making throughout the disease continuum.” “Later-changing Core 2 biomarkers (biofluid and tau PET) can provide prognostic information, and when abnormal, will increase confidence that AD is contributing to symptoms.”⁵⁸

The Core 1 biomarkers are A (A β proteinopathy) and T1 (phosphorylated and secreted AD tau). The fluid analyte for A (A β proteinopathy) is A β 42 and it is imaged with Amyloid PET. The fluid analytes of T1 (phosphorylated and secreted AD tau) are p-tau217, p-tau181, and p-tau231. The core 2 biomarker is T2 (AD tauproteinopathy). The fluid analytes of T2 (AD tauproteinopathy) are MTBR-tau243, other phosphorylated tau forms (e.g., p-tau205), non-phosphorylated mid-region tau fragments and it is imaged by Tau PET. Note that P-tau231, p-tau205, MTBR-tau243, and non-phosphorylated tau fragments “have not undergone the same level of validation testing as other Core biomarkers.”⁵⁸

For the diagnosis of AD, “we propose that abnormality on specific Core 1 biomarkers is sufficient to diagnose AD. Specifically, we propose that the following can be diagnostic of AD: amyloid PET; CSF A β 42/40, CSFp-tau 181/A β 42, CSF t-tau/A β 42; or “accurate” plasma assays where “accurate” can be defined as accuracy that is equivalent to approved CSF assays in detecting abnormal amyloid PET in the intended-use population.” “Core 2 biomarkers have many uses but most often would not be used as standalone diagnostic tests for AD.”⁵⁸

Reimbursement Policy:

Biochemical Markers of Alzheimer Disease and Dementia - Lab Benefit Program (LBM)

The guidelines note that “not all available Core 1 biomarker tests have sufficient accuracy to be suitable for diagnosis. Currently, we regard the following to be diagnostic of AD: amyloid PET, cerebrospinal fluid (CSF) A β 42/40, CSF p-tau 181/A β 42, CSF t-tau/A β 42, ‘accurate’ plasma assays, or combinations of these. In most situations different Core 1 biomarkers should be interchangeable for the detection of AD neuropathologic change (ADNPC) and, hence, for the diagnosis of AD.”⁵⁸

Alzheimer’s Association and Society of Nuclear Medicine and Molecular Imaging (SNMMI)

In 2025, the Alzheimer’s Association and SNMMI published “Updated Appropriate Use Criteria for Amyloid and Tau PET.” “The following general principles served as the ‘litmus test’ for appropriateness of amyloid or tau imaging across all clinical scenarios: AD is considered a likely etiology of cognitive impairment, but the etiology remains uncertain after a comprehensive evaluation by a dementia expert. Knowledge of the presence or absence of amyloid tau pathology is expected to help establish the etiology of impairment and alter management. The workgroup recommends that these principles be met in all patients referred for clinical amyloid/tau PET across all clinical scenarios.”⁵⁹

The guidelines outline 17 clinical scenario and define the appropriateness of Amyloid and Tau PET Imaging in each scenario. “A score of 1–3 is rarely appropriate, of 4–6 is uncertain, and of 7–9 is appropriate.”⁵⁹

- “Patients who are CU, who are not considered to be at increased risk for AD based on age, known APOE4 genotype, or multigenerational family history. Consensus ratings: Amyloid - 1 Highly confident that the use of the tracer is rarely appropriate. Tau - 1 Highly confident that the use of the tracer is rarely appropriate.”
- “Patients who are CU but considered to be at increased risk for AD based on age, known APOE4 genotype, or multigenerational family history. Consensus ratings: Amyloid - 2 Moderately confident that the use of the tracer is rarely appropriate. Tau - 1 Highly confident that the use of the tracer is rarely appropriate.”
- “Patients with SCD (CU based on objective testing) who are not considered to be at elevated risk for AD based on age, known APOE4 genotype, or multigenerational family history. Consensus ratings: Amyloid - 2 Moderately confident that the use of the tracer is rarely appropriate. Tau - 1 Highly confident that the use of the tracer is rarely appropriate.”
- “Patients with SCD (CU based on objective testing) who are considered to be at increased risk for AD based on age, known APOE4 genotype, or multigenerational family history. Consensus ratings: Amyloid - 6 Uncertain, but possibility that the use of the tracer is appropriate. Tau - 2 Moderately confident that the use of the tracer is rarely appropriate.”
- “Patients presenting with MCI or dementia who are younger than 65 years and in whom AD pathology is suspected. Consensus ratings: Amyloid - 9 High confidence that use of the tracer is appropriate. Tau - 8 Moderately confident that use of the tracer is appropriate.”
- “Patients presenting with MCI or dementia syndrome that is often consistent with AD pathology (amnestic presentation) with onset at 65 years or older. Consensus ratings: Amyloid - 8 Moderately confident that use of the tracer is appropriate. Tau - 6 Uncertain, but possibility that the use of the tracer is appropriate.”
- “Patients presenting with MCI or dementia syndrome that could be consistent with AD pathology but has atypical features (e.g., non-amnestic clinical presentation, rapid or slow progression, etiologically mixed presentation). Consensus ratings: Amyloid - 8 Moderately confident that use of the tracer is appropriate. Tau - 7 Only somewhat confident that the use of the tracer is appropriate.”

Reimbursement Policy:

Biochemical Markers of Alzheimer Disease and Dementia - Lab Benefit Program (LBM)

- “To determine disease severity or track disease progression in patients with an established biomarker-supported diagnosis of MCI or dementia due to AD pathology. Consensus ratings: Amyloid - 1 Highly confident that the use of the tracer is rarely appropriate. Tau - 4 Uncertain, but possible that the use of the tracer is rarely appropriate.”
- “Patients presenting with prodromal Lewy body disease or DLB. Consensus ratings: Amyloid - 2 Moderately confident that the use of the tracer is rarely appropriate. Tau - 4 Uncertain, but possible that the use of the tracer is rarely appropriate.”
- “Patients with MCI or dementia with recent CSF biomarker results that are conclusive (whether consistent or not consistent with underlying AD pathology). Consensus ratings: Amyloid - 3 Only somewhat confident that the use of the tracer is rarely appropriate. Tau - 6 Uncertain, but possibility that the use of the tracer is appropriate.”
- “Patients with MCI or dementia with equivocal or inconclusive results on recent CSF biomarkers. Consensus ratings: Amyloid - 8 Moderately confident that use of the tracer is appropriate. Tau - 6 Uncertain, but possibility that the use of the tracer is appropriate.”
- “To inform the prognosis of patients presenting with MCI due to clinically suspected AD pathology. Consensus ratings: Amyloid - 8 Moderately confident that use of the tracer is appropriate. Tau - 7 Only somewhat confident that the use of the tracer is appropriate.”
- “To inform the prognosis of patients presenting with dementia due to clinically suspected AD pathology. Consensus ratings: Amyloid - 4 Uncertain, but possible that the use of the tracer is rarely appropriate. Tau - 7 Only somewhat confident that the use of the tracer is appropriate.”
- “To determine eligibility for treatment with an approved amyloid-targeting therapy. Consensus ratings: Amyloid - 9 High confidence that use of the tracer is appropriate. Tau - 8 Moderately confident that use of the tracer is appropriate.”
- “To monitor response among patients who have received an approved amyloid-targeting therapy. Consensus ratings: Amyloid - 8 Moderately confident that use of the tracer is appropriate. Tau - 5 Uncertain, evidence is inconclusive or lacking.”
- “Nonmedical usage (e.g., legal, insurance coverage, or employment screening). Consensus ratings: Amyloid - 1 Highly confident that the use of the tracer is rarely appropriate. Tau - 1 Highly confident that the use of the tracer is rarely appropriate.”
- “In lieu of genotyping for suspected autosomal dominant mutation carriers. Consensus ratings: Amyloid - 1 Highly confident that the use of the tracer is rarely appropriate. Tau - 1 Highly confident that the use of the tracer is rarely appropriate.”

Expert Working Group for the EU Joint Program—Neurodegenerative Disease Research (JPND) BIOMARKAPD Program

An expert working group, comprised of 28 international members, was convened to develop recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. “The working group recommended using the CSF biomarkers in MCI as an add-on to clinical evaluation alone for predicting functional decline or progression to AD dementia and, based on the available evidence, the recommendation was strong. However, in comparison with the outcome of using hippocampal atrophy as a biomarker, the working group issued a weak recommendation to incorporate CSF biomarkers in the diagnostic workup compared with hippocampal atrophy.”

Reimbursement Policy:

Biochemical Markers of Alzheimer Disease and Dementia - Lab Benefit Program (LBM)

Because of insufficient evidence, the working group could not recommend CSF biomarkers as an alternative to FDG-PET or amyloid-PET in predicting future decline or conversion. The working group recommended using CSF biomarkers to inform future disease management, but the strength of this recommendation was weak because of the small amount of evidence.”⁶⁰

Six clinical questions were asked by Simonsen, et al. (2017):

1. “In patients with MCI, will CSF biomarkers (alone or in combination) compared with (A) clinical measures alone and/or (B) other imaging biomarkers identify or exclude AD as the cause of MCI?”
 - a. Final recommendation: N/A
2. “In patients with MCI, will CSF biomarkers (alone or in combination) compared with (A) clinical measures alone and/or (B) other imaging biomarkers predict conversion to AD dementia within 3 years?”
 - a. Final recommendation: Yes, strong
3. “In patients with MCI, will CSF biomarkers (alone or in combination) compared with (A) clinical measures alone and/or (B) other imaging biomarkers predict functional or cognitive decline?”
 - a. Final recommendation: Yes, strong
4. “In patients with MCI, will CSF biomarkers (alone or in combination) compared with (A) clinical measures alone and/or (B) other imaging biomarkers change disease management?”
 - a. Yes, weak
5. “In patients with MCI, will CSF biomarkers (alone or in combination) compared with (A) clinical measures alone and/or (B) other imaging biomarkers improve patient well-being?”
 - a. Yes, weak
6. “In patients with MCI, will CSF biomarkers (alone or in combination) compared with (A) clinical measures alone and/or (B) other imaging biomarkers reduce health care costs?”
 - a. No, weak

Additional recommendations were made by Herukka, et al. (2017) for CSF AD biomarkers in the diagnostic evaluation of mild cognitive impairment. The same six clinical questions were asked as above by Simonsen et al. (2017):

1. “In patients with MCI, will CSF biomarkers (alone or in combination) compared with (A) clinical measures alone and/or (B) other imaging biomarkers identify or exclude AD as the cause of MCI?”
 - a. Final recommendation: N/A
2. “In patients with MCI, will CSF biomarkers (alone or in combination) compared with (A) clinical measures alone and/or (B) other imaging biomarkers predict conversion to AD dementia within 3 years?”
 - a. Final recommendation: Yes, strong
3. “In patients with MCI, will CSF biomarkers (alone or in combination) compared with (A) clinical measures alone and/or (B) other imaging biomarkers predict functional or cognitive decline?”
 - a. Final recommendation: Yes, strong

Reimbursement Policy:

Biochemical Markers of Alzheimer Disease and Dementia - Lab Benefit Program (LBM)

4. “In patients with MCI, will CSF biomarkers (alone or in combination) compared with (A) clinical measures alone and/or (B) other imaging biomarkers change disease management?”
 - a. Yes, weak
5. “In patients with MCI, will CSF biomarkers (alone or in combination) compared with (A) clinical measures alone and/or (B) other imaging biomarkers improve patient well-being?”
 - a. Yes, weak
6. “In patients with MCI, will CSF biomarkers (alone or in combination) compared with (A) clinical measures alone and/or (B) other imaging biomarkers reduce health care costs?”
 - a. No, weak

National Institute on Aging (NIA, NIH) and Alzheimer’s Association

In 2011, the National Institute on Aging and Alzheimer’s Association workgroups published guidelines for the diagnosis of AD. The authors also note that “Two fundamental issues about individuals with MCI may be answered by the use of biomarkers: (1) To establish support for the underlying etiology of the clinical syndrome in an individual with MCI, which will have major importance for choosing the correct therapy, when effective treatments are available. To determine the likelihood of cognitive and functional progression for an individual MCI patient to a more severe stage of MCI or to dementia, and the likelihood that this progression will occur within a defined period.”⁶² The authors also note that “in these recommendations, CSF tau is considered to be a strong marker of the neuronal injury associated with AD. However, the two biomarkers in combination are extremely informative. Together with low CSF A β 42, elevated CSF tau provides a high likelihood of progression to AD in patients with MCI;” however, because many biochemical events may be associated with AD, the authors confirm that “Additional work in this area is needed to know how useful these markers will be.”⁶²

In 2018, guidelines were published by the National Institute on Aging and Alzheimer’s Association for the preclinical, mild cognitive impairment, and dementia stages of AD, and are intended for use in observational and interventional research, not routine clinical care. These guidelines state that “there is now a growing consensus that application of biomarkers should be harmonized conceptually across the disease continuum and that biomarkers of neurodegeneration are not equivalent to those reflecting amyloid and pathologic tau accumulation.”⁶³ Further, regarding the guidelines noted above from 2011, the authors state that “Studies published since 2011 have reinforced the idea that certain imaging and CSF biomarkers are valid proxies for neuropathologic changes of AD.... additional research has highlighted the fact that measures of neurodegeneration or neuronal injury that are commonly used in AD research—magnetic resonance imaging (MRI), fluoro-deoxyglucose (FDG) PET, and CSF total tau (T-tau)—are not specific for AD but rather are nonspecific indicators of damage that may derive from a variety of etiologies, for example, cerebrovascular injury.”⁶³ The authors also state that the “data firmly establish that more advanced disease defined by biomarkers predicts greater likelihood of and more rapid cognitive decline. Thus, a solid evidence base exists proving that combinations of biomarker abnormalities are useful for staging the Alzheimer’s continuum.”⁶³

World Health Organization (WHO)

The WHO published a guide on “preferred product characteristics of blood-based biomarker diagnostics for Alzheimer disease” as part of their global dementia action plan. The resource is intended to guide the development and implementation of dementia diagnosis tools around the world. The WHO states “To date, biomarkers found in blood – commonly referred as blood-based biomarkers – have demonstrated, in research contexts, that they can accurately identify and quantify markers of pathophysiological processes in disease development. Given the strong correlation found in most cases between biomarker measurement in blood and in CSF, the use of blood is preferred over CSF due to its safer sample collection, reduced need for specialized workforce and lower infrastructure requirements.”⁶⁴

Reimbursement Policy:

Biochemical Markers of Alzheimer Disease and Dementia - Lab Benefit Program (LBM)

The WHO preferred product characteristics include:⁶⁴

- Intended use: “Aid the diagnosis of Alzheimer disease.”
- Target Population: “Individuals with cognitive impairment consistent with the ICD-11 definition, established by a trained health-care professional. Cognitive symptoms are progressive and represent a decline from previous cognitive function. Exclusion criteria: For this PPC, individuals without established cognitive impairment as described above, as well as individuals undergoing treatment with disease-modifying therapies or participating in clinical trials for such therapies should not be offered the test for the intended use described.”
- Specimen Type: “Peripheral blood. Dried blood or plasma spots.”
- Clinical performance: “Minimum sensitivity and specificity of 90% when compared with a valid reference standard (e.g. neuropathology, amyloid PET or approved CSF assays) in the target population and for a diagnostic use case. Validation and assessment of clinical relevance and performance of the biomarker tests must be conducted in the intended use setting, especially in [low- and middle-income countries], in addition to studies in more highly controlled environments. The assay should minimize, as far as is possible, the proportion of indeterminate and invalid results.”

The WHO notes, for the target population, “The symptoms consistent with the ICD-11 definition include a slow but steady decline from a previous level of cognitive functioning with impairment across multiple domains, such as memory, executive functions, attention, language, social cognition and judgment, psychomotor speed, visuospatial or visuospatial abilities. Alzheimer disease may be accompanied by mental and behavioral symptoms such as depressed mood, apathy, and irritability.” For the specimen type, “Different anti-coagulants should be evaluated and validated for maximum biomarker stability.”⁶⁴

Global Biomarker Standardization Consortium (GBSC)

The GBSC of the Alzheimer’s Association has noted that before biomarkers can be used in clinical practice, they “must be standardized and validated on a global scale.”⁶⁵

American Academy of Neurology (AAN)

In 2001, the Quality Standards Committee of the American Academy of Neurology issued a “Practice parameter: Diagnosis of dementia (an evidence-based review).” Relevant statements to the current policy include the following:

“...no laboratory tests have yet emerged that are appropriate or routine use in the clinical evaluation of patients with suspected AD. Several promising avenues genotyping, imaging and biomarkers are being pursued, but proof that a laboratory test has value is arduous. Ultimately, the putative diagnostic test must be administered to a representative sample of patients with dementia who eventually have pathologic confirmation of their diagnoses. A valuable test will be one that increases diagnostic accuracy over and above a competent clinical diagnosis.”

“There are no CSF or other biomarkers recommended for routine use in determining the diagnosis of AD at this time.”⁶⁶

Dementia with Lewy Bodies (DLB) Consortium

The DLB Consortium published a consensus report on the diagnosis and management of dementia with Lewy bodies, which are characteristic of Alzheimer’s Disease and other neurological conditions. The Consortium states that “direct biomarker evidence of LB-related pathology is not yet available for clinical diagnosis.”⁶⁷

Reimbursement Policy:

Biochemical Markers of Alzheimer Disease and Dementia - Lab Benefit Program (LBM)

Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry

The Federation published an update on cerebrospinal fluid (CSF) and blood biomarkers for neurodegenerative dementias. The Federation considers blood-based biomarkers to “offer an ideal complementary step to advanced CSF and neuroimaging biomarkers and can serve as the first-step in a multi-stage process,” although these biomarkers still require validation and “a great deal of additional work.”⁶⁸

International Working Group (IWG)

Dubois, et al. (2014) published a position paper which presents a new diagnostic algorithm for AD which states: “A β 1–42 and tau (T-tau or P-tau) should be used in combination, and the CSF AD signature, which combines low A β 1 and high T-tau or P-tau concentrations, significantly increases the accuracy of AD diagnosis even at a prodromal stage. This combination reaches a sensitivity of 90–95% and a specificity of about 90% in AD. CSF biomarkers cannot be used as standalone tests and should be interpreted in a larger clinical context with confounding factors considered. An important concern is the large variability in CSF measures between laboratories and across techniques, and the lack of agreement on cutoff thresholds. These variations have made direct comparison of study results difficult. Several programmes of standardisation, including the Alzheimer’s Association Quality Control programme for CSF biomarkers, initiatives within the Joint Program for Neurodegenerative Diseases, and the Global Biomarker Standardisation Consortium, and by industry, will minimise between-laboratory variations in the future and allow identification of uniform cutoff levels.” In their 2021 IWG position paper, the group states “Overall, evidence for the use of biomarkers in clinical practice remains highly disputed and suffers from a dearth of evidence-based data to recommend biomarker assessments for cognitively unimpaired individuals.”⁷⁰

The IWG describes specific biochemical evidence in their definitions of AD:

“In-vivo evidence of Alzheimer’s pathology (one of the following):

- Decreased A β 1–42 together with increased T-tau or P-tau in CSF
- Increased tracer retention on amyloid PET
- AD autosomal dominant mutation present (in PSEN1, PSEN2, or APP).”⁶⁹

In their updated proposed recommendations, the IWG included the following relevant information:

1. “The diagnosis of Alzheimer’s disease is clinical–biological. It requires the presence of both a specific clinical phenotype of Alzheimer’s disease (phenotype positive) and biomarker evidence of Alzheimer’s disease pathology (amyloid-positive and tau positive).
2. In people who have...common phenotypes, amyloid and tau biomarker positivity establishes an Alzheimer’s disease diagnosis (table 2). The positivity of both amyloid and tau biomarkers is required because an amnesic phenotype with only amyloid positivity is not specific to Alzheimer’s disease and is seen in other neurodegenerative diseases with amyloid copathology (including LATE and dementia with Lewy bodies) or in patients with cerebral amyloid angiopathy and amnesic vascular cognitive impairment. However, an isolated amnesic syndrome of the hippocampal type with only tau biomarker positivity can occur in primary age-related tauopathy or in atypical presentations of mixed 3 repeat or 4 repeat tau frontotemporal lobar degeneration. Finally, uncommon phenotypes with positive Alzheimer’s disease biomarkers should not be a-priori classified as an established Alzheimer’s disease (table 2); in such cases the clinician could deem that Alzheimer’s disease is not the dominant pathology driving the clinical phenotype but only a copathology.

Reimbursement Policy:

Biochemical Markers of Alzheimer Disease and Dementia - Lab Benefit Program (LBM)

3. Recommended biomarker measures for amyloid β pathology are low CSF A β 42, increased CSF A β 40–A β 42 ratio (which is, if possible, preferred to low CSF A β 42) or high tracer retention in amyloid PET. For tau pathology, we recommend high CSF phosphorylated tau (not total tau because of low specificity) or increased ligand retention in tau PET. Recommendation of amyloid PET and tau PET for use in clinical practice is conditional on regulatory approval and reimbursement by payers in different countries.
4. CSF investigation is prioritized because it provides simultaneous information on the two types of biomarkers (amyloid β and tau) and is less expensive than amyloid PET, tau PET, or both. If lumbar puncture is contraindicated, PET investigations are an alternative.
5. In clinical practice, plasma biomarkers for amyloid β and tau pathology are not currently recommended. Although promising, plasma biomarkers require further standardization and validation before they can be broadly regarded as secure evidence of Alzheimer's disease pathology (amyloid-positive and tau-positive).
6. In clinical practice, the investigation of pathophysiological biomarkers in cognitively unimpaired individuals is not recommended, given the current inability to predict reliable clinical trajectories of people who are asymptomatic with biomarker positive status (amyloid-positive and tau-positive). In the future, if therapies or prevention programmes show substantial efficacy in delaying onset of disease, that will probably change the need for biomarker investigations in these individuals, although the problem of the prediction of clinical trajectories in cognitively unimpaired biomarker-positive individuals will still remain.
7. Physicians are recommended to evaluate the added-value of biomarker investigation for each symptomatic patient objectively, according to the clinical situation (age, risk of comorbidity, complexity of the phenotype), the life context, the wishes of the patient to know the most likely diagnosis, the possibility of participation in a disease-modifying trial, and the appreciation of how this information will change the management of the patient. Biomarker investigations can also be limited by the availability, cost, and health-care payment coverage of biomarkers across countries, centres, and clinical situations."⁷⁰

Reimbursement Policy:

Biochemical Markers of Alzheimer Disease and Dementia - Lab Benefit Program (LBM)

Table 2:⁷⁰

	Likelihood of Alzheimer's disease as a primary diagnosis	Further investigation
Common Alzheimer's disease phenotypes (amnestic variant, logopenic variant of primary progressive aphasia, and posterior cortical atrophy)		
Amyloid positive, tau positive	Highly probable-established	None required
Amyloid positive, tau unknown	Probable	Consider a tau measure (PET, CSF)
Amyloid positive, tau negative	Probable	Consider an additional tau measure (PET, CSF)
Tau positive, amyloid unknown	Possible	Consider an amyloid measure (PET, CSF)
Tau positive, amyloid negative	Possible	Consider an additional amyloid measure (PET, CSF)
Amyloid negative, tau unknown	Unlikely	Full investigation of cause and consider a tau measure (PET, CSF) ⁺
Amyloid unknown, tau negative	Unlikely	Full investigation of cause and consider an amyloid measure (PET, CSF) ⁺
Amyloid negative, tau negative	Highly unlikely-excluded	Full investigation of cause ⁺⁺
Amyloid unknown, tau unknown	Non-assessable	Consider tau and amyloid measures (PET, CSF)
Uncommon Alzheimer's disease phenotypes (behavioural or dysexecutive variant, corticobasal syndrome, non-fluent variant of primary progressive aphasia, and semantic variant of primary progressive aphasia)		
Amyloid positive, tau positive	Probable	None required; careful follow-up needed: an incongruent clinical phenotype and neurodegeneration pattern should trigger a new investigation ⁺
Amyloid positive, tau unknown	Possible	Consider a tau measure (PET, CSF)
Amyloid positive, tau negative	Possible	Consider an additional tau measure (PET, CSF)
Tau positive, amyloid unknown	Unlikely	Full investigation of cause and consider an amyloid measure (PET, CSF)
Tau positive, amyloid negative	Unlikely	Full investigation of cause ⁺
Amyloid negative, tau unknown	Highly unlikely-excluded	Full investigation of cause ⁺⁺
Amyloid negative, tau negative	Highly unlikely-excluded	Full investigation of cause ⁺⁺
Amyloid unknown, tau negative	Highly unlikely-excluded	Full investigation of cause ⁺⁺
Amyloid unknown, tau unknown	Non-assessable	Full investigation of cause and consider tau and amyloid measures (PET, CSF) ⁺
Other phenotypes (eg, dementia with Lewy bodies, Richardson syndrome, Huntington's disease, and amyotrophic lateral sclerosis)		
Amyloid positive, or tau positive, or both	Unlikely	Full investigation of cause ⁺
Amyloid negative, tau unknown	Highly unlikely-excluded	Full investigation of cause ⁺
Amyloid unknown, tau negative	Highly unlikely-excluded	Full investigation of cause ⁺
Amyloid negative, tau negative	Highly unlikely-excluded	Full investigation of cause ⁺
Amyloid unknown, tau unknown	Highly unlikely-excluded	Full investigation of cause ⁺

United States Preventive Services Task Force (USPSTF)

In 2020, the USPSTF published a recommendation stating that “current evidence is insufficient to assess the balance of benefits and harms of screening for cognitive impairment in older adults.”⁷¹

Reimbursement Policy:

Biochemical Markers of Alzheimer Disease and Dementia - Lab Benefit Program (LBM)

European Federation of Neurological Societies (EFNS)

The EFNS published updated guidelines in 2012 for the diagnosis and management of disorders associated with dementia. These guidelines state that “Routine CSF analysis may help to rule out or rule in certain infectious causes (Good Practice Point). CSF abeta 1-42/tau/p-tau assessment helps to differentiate AD (Level B). Assessment of CSF total tau and 14-3-3 protein is recommended in rapidly progressive dementia when sCJD is suspected (Good Practice Point).”⁷²

Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD)

In 2020, the CCCDTD released recommendations on the diagnosis and treatment of dementia. The guidelines state that “CSF analysis is not recommended routinely, but it can be considered in dementia patients with diagnostic uncertainty and onset at an early age (<65) to rule out Alzheimer’s disease (AD) pathophysiology.” The guidelines also state that “CSF analysis can also be considered in dementia patients with diagnostic uncertainty and predominance of language, visuospatial, dysexecutive, or behavioral features to rule out AD pathophysiology.”⁷³

National Institute for Health and Care Excellence (NICE)

In 2018, NICE released guidelines on assessment, management, and support for people living with dementia. With regards to further testing, NICE states to only consider them if “it would help diagnosed a dementia subtype and knowing more about the dementia subtype would change management.”

The NICE recommendations for further tests for Alzheimer’s disease are delineated below:

- “If the diagnosis is uncertain... and Alzheimer’s disease is suspected, consider either:
 - FDG-PET (fluorodeoxyglucose-positron emission tomography-CT), or perfusion SPECT (single-photon emission CT) if FDG-PET is unavailable **OR**
 - Examining cerebrospinal fluid for:
 - Either total tau or total tau and phosphorylated-tau 181 **and**
 - Either amyloid beta 1-42 or amyloid beta 1-42 and amyloid beta 1-40.
 - If a diagnosis cannot be made after one of these tests, consider using the other one.
- Be aware that the older a person is, the more likely they are to get a false positive with cerebrospinal fluid examination.
- Do not rule out Alzheimer’s disease based solely on the results of CT or MRI scans.
- Do not use Apolipoprotein E genotyping or electroencephalography to diagnose Alzheimer’s disease.
- Be aware that young-onset Alzheimer’s disease has a genetic cause in some people.”⁷⁴

Reimbursement Policy:

Biochemical Markers of Alzheimer Disease and Dementia - Lab Benefit Program (LBM)

Applicable State and Federal Regulations:

DISCLAIMER: If there is a conflict between this Policy and any relevant, applicable government policy for a particular member [e.g., Local Coverage Determinations (LCDs) or National Coverage Determinations (NCDs) for Medicare and/or state coverage for Medicaid], then the government policy will be used to make the determination. For the most up-to-date Medicare policies and coverage, please visit the Medicare search website: <https://www.cms.gov/medicare-coverage-database/search.aspx>. For the most up-to-date Medicaid policies and coverage, visit the applicable state Medicaid website.

Food and Drug Administration (FDA)

Many labs have developed specific tests that they must validate and perform in house. These laboratory-developed tests (LDTs) are regulated by the Centers for Medicare and Medicaid (CMS) as high-complexity tests under the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88). LDTs are not approved or cleared by the U. S. Food and Drug Administration; however, FDA clearance or approval is not currently required for clinical use.

On February 15, 2018, the FDA released a statement concerning the advancement of the development of novel treatments for neurological conditions, including Alzheimer disease. FDA Commissioner Scott Gottlieb, M.D., states, “Symptoms and progression of neurological diseases can also vary significantly across patients, and even within patients, and across organ systems. Some diseases, like Alzheimer’s, may progress invisibly for years. Once clinical symptoms become apparent, significant function may already be lost. These issues can make drug development more challenging for companies and are deeply frustrating for patients and caregivers living with these serious and life-threatening conditions. The FDA recognizes the urgent need for new medical treatments for many serious conditions including neurological disorders such as muscular dystrophies, amyotrophic lateral sclerosis (ALS), Alzheimer’s disease (AD), migraine and epilepsy. This requires us to become more nimble, collaborative and patient-focused. As part of our ongoing efforts to expand access to safe and effective treatment options across all disease areas and promote innovation, the FDA is modernizing multiple aspects of our drug regulatory programs – including how we communicate scientific and regulatory guidance for drug development.”⁷⁵ Concurrently, the FDA released a guidance for industry concerning AD for public comment for 90 days. Within the guidance, the FDA states, “FDA supports and endorses the use of diagnostic criteria that are based on a contemporary understanding of the pathophysiology and evaluation of AD... Important findings applicable to the categorization of AD along its continuum of progression include the presence of pathophysiological changes as measured by biomarkers, the presence or absence of detectable abnormalities on sensitive neuropsychological measures, and the presence or absence of functional impairment manifested as meaningful daily life impact the present with subjective complaints or reliable observer reports.”⁷⁶ The final draft of the guidance should be released in the future after the public comment period has concluded.

In 2022, the FDA permitted marketing for the Fujirebio Diagnostics Lumipulse® G β -Amyloid Ratio (1-42/1-40) test, which is administrated under a CMS laboratory certification process. It is intended to measure the ratio of beta-amyloid 1-42 and beta-amyloid 1-40 concentrations in CSF, which can help predict the likelihood of amyloid plaque formation in potential AD. This assay received the “Breakthrough Device Designation” from the FDA in May 2022.²⁵

Roche Diagnostics received 501(k) clearance from the FDA for their Elecsys® beta-Amyloid (1-42) CSF II (Abeta42) and Elecsys® Phospho-Tau (181P) CSF (pTau181) assays in 2022 for adults 55 years and older who are evaluated for the disease to generate a pTau181/Abeta42 ratio value. In June 2023, Roche Diagnostics also received 501(k) clearance from the FDA for the Elecsys® beta-Amyloid (1-42) CSF II (Abeta42) and Elecsys® Total-Tau CSF assays (tTau) in the same population through the tTau/Abeta42 ratio, and will be available in Q4 2023.²⁷

Reimbursement Policy:

Biochemical Markers of Alzheimer Disease and Dementia - Lab Benefit Program (LBM)

In 2025, the FDA permitted marketing for the Fujirebio Diagnostics, Inc. Lumipulse G pTau217/ β -Amyloid 1-42 Plasma Ratio test. The test is intended to “identify patients with amyloid pathology associated with Alzheimer's disease.” The test is designed to be used for patients over the age of 50 who present with signs or symptoms of cognitive decline. It is noted that the test is not intended to be used as a screening or stand-alone diagnostic tool, and results must be analyzed in combination with other clinical information about the patient.⁷⁷

Applicable CPT/HCPCS Procedure Codes:

CPT	Code Description
82233	Beta-amyloid; 1-40 (Abeta 40)
82234	Beta-amyloid; 1-42 (Abeta 42)
83520	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified
83884	Neurofilament light chain (NfL)
84393	Tau, phosphorylated (eg, pTau 181, pTau 217), each
84394	Tau, total (tTau)
0358U	Neurology (mild cognitive impairment), analysis of β -amyloid 1-42 and 1-40, chemiluminescence enzyme immunoassay, cerebral spinal fluid, reported as positive, likely positive, or negative Proprietary test: Lumipulse® G β -Amyloid Ratio (1-42/1-40) Test Lab/Manufacturer: Fujirebio Diagnostics, Inc

Current Procedural Terminology© American Medical Association. All Rights reserved.

Procedure codes appearing in Medical Policy documents are included only as a general reference tool for each policy. They may not be all-inclusive.

Evidence-based Scientific References:

1. Karch CM, Cruchaga C, Goate AM. Alzheimer's disease genetics: from the bench to the clinic. *Neuron*. 2014;83(1):11-26. doi:10.1016/j.neuron.2014.05.041
2. WHO. Dementia. <https://www.who.int/news-room/fact-sheets/detail/dementia>
3. Goldman JS, Hahn SE, Catania JW, et al. Genetic counseling and testing for Alzheimer disease: Joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. *Genet Med*. 2011;13(6):597-605. doi:10.1097/GIM.0b013e31821d69b8
4. Gatz M, Reynolds CA, Fratiglioni L, et al. Role of genes and environments for explaining Alzheimer disease. *Archives of general psychiatry*. 2006;63(2):168-74. doi:10.1001/archpsyc.63.2.168
5. Kramarow E, Tejada-Vera B. Adjusted Death Rates* from Dementia,† by Sex, Race, and Hispanic Origin — National Vital Statistics System, United States, 2017. *MMWR Morb Mortal Wkly Rep*. 2019;68:670.
6. Shea YF, Chu LW, Chan AO, Ha J, Li Y, Song YQ. A systematic review of familial Alzheimer's disease: Differences in presentation of clinical features among three mutated genes and potential ethnic differences. *Journal of the Formosan Medical Association = Taiwan yi zhi*. 2016;115(2):67-75. doi:10.1016/j.jfma.2015.08.004

Reimbursement Policy:

Biochemical Markers of Alzheimer Disease and Dementia - Lab Benefit Program (LBM)

7. Sala Frigerio C, De Strooper B. Alzheimer's Disease Mechanisms and Emerging Roads to Novel Therapeutics. *Annual Review of Neuroscience*. 2016;39(1):57-79. doi:10.1146/annurev-neuro-070815-014015
8. Van Cauwenberghe C, Van Broeckhoven C, Sleegers K. The genetic landscape of Alzheimer disease: clinical implications and perspectives. *Genet Med*. 2016;18(5):421-30. doi:10.1038/gim.2015.117
9. Arranz AM, De Strooper B. The role of astroglia in Alzheimer's disease: pathophysiology and clinical implications. *Lancet Neurol*. 2019;18(4):406-414. doi:10.1016/s1474-4422(18)30490-3
10. Peterson RC. Mild cognitive impairment: Prognosis and treatment. Updated June 7, 2024. <https://www.uptodate.com/contents/mild-cognitive-impairment-prognosis-and-treatment>
11. Bennett DA, Wilson RS, Schneider JA, et al. Natural history of mild cognitive impairment in older persons. *Neurology*. 2002;59(2):198-205.
12. Hansson O, Lehmann S, Otto M, Zetterberg H, Lewczuk P. Advantages and disadvantages of the use of the CSF Amyloid β (A β) 42/40 ratio in the diagnosis of Alzheimer's Disease. *Alzheimers Res Ther*. 2019;11(1):34. doi:10.1186/s13195-019-0485-0
13. Wolk DA, Dickerson BC. Clinical features and diagnosis of Alzheimer disease. Updated September 30, 2024. <https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-alzheimer-disease>
14. Schaffer C, Sarad N, DeCrumpe A, et al. Biomarkers in the Diagnosis and Prognosis of Alzheimer's Disease. *Journal of laboratory automation*. 2015;20(5):589-600. doi:10.1177/2211068214559979
15. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. *Jama*. 1997;278(16):1349-56.
16. Patel S, Shah RJ, Coleman P, Sabbagh M. Potential peripheral biomarkers for the diagnosis of Alzheimer's disease. *International journal of Alzheimer's disease*. 2011;2011:572495. doi:10.4061/2011/572495
17. Blennow K, Zetterberg H, Fagan AM. Fluid biomarkers in Alzheimer disease. *Cold Spring Harbor perspectives in medicine*. 2012;2(9):a006221. doi:10.1101/cshperspect.a006221
18. Lonnberg A. Biomarkers for Alzheimer disease in cerebrospinal fluid, urine, and blood. *Molecular diagnosis & therapy*. 2008;12(5):307-20.
19. Jiang L, Dong H, Cao H, Ji X, Luan S, Liu J. Exosomes in Pathogenesis, Diagnosis, and Treatment of Alzheimer's Disease. *Med Sci Monit*. 2019;25:3329-3335. doi:10.12659/msm.914027
20. Huan T, Tran T, Zheng J, et al. Metabolomics Analyses of Saliva Detect Novel Biomarkers of Alzheimer's Disease. *Journal of Alzheimer's disease : JAD*. 2018;65(4):1401-1416. doi:10.3233/jad-180711
21. François M, Bull CF, Fenech MF, Leifert WR. Current State of Saliva Biomarkers for Aging and Alzheimer's Disease. *Curr Alzheimer Res*. 2019;16(1):56-66. doi:10.2174/1567205015666181022094924
22. Morris JC, Blennow K, Froelich L, et al. Harmonized diagnostic criteria for Alzheimer's disease: recommendations. *Journal of internal medicine*. 2014;275(3):204-13. doi:10.1111/joim.12199
23. C2N. SYN-ONE TEST®. <https://c2n.com/news-releases/2019/01/29/2019-1-24-c2n-diagnostics-receives-breakthrough-device-designation-from-us-fda-for-blood-test-to-screen-for-alzheimers-disease-risk>
24. Fujirebio. Lumipulse® G β -Amyloid Ratio (1-42/1-40). <https://www.fujirebio.com/en-us/products-solutions/lumipulse-g-beta-amyloid-ratio-142-140>
25. FDA. FDA Permits Marketing for New Test to Improve Diagnosis of Alzheimer's Disease. <https://www.prnewswire.com/news-releases/fda-permits-marketing-for-new-test-to-improve-diagnosis-of-alzheimers-disease-301540093.html>
26. Roche. Roche Alzheimer's disease Cerebrospinal Fluid (CSF) assays receive FDA clearance, supporting more accurate and timely diagnosis. <https://www.globenewswire.com/news-release/2022/12/08/2569879/0/en/Roche-Alzheimer-s-disease-Cerebrospinal-Fluid-CSF-assays-receive-FDA-clearance-supporting-more-accurate-and-timely-diagnosis.html>
27. Roche. Roche receives FDA clearance for additional Alzheimer's disease Cerebrospinal Fluid (CSF) assays, supporting timely diagnosis and treatment decision-making. <https://diagnostics.roche.com/us/en/news-listing/2023/roche-fda-clearance-additional-alzheimers-disease-cerebrospinal-fluid-ttau.html>

Reimbursement Policy:

Biochemical Markers of Alzheimer Disease and Dementia - Lab Benefit Program (LBM)

28. BusinessWire. Quanterix Launches LucentAD Biomarker Blood Test to Aid Physician Diagnosis of Alzheimer's Disease in Patients. <https://www.businesswire.com/news/home/20230706742971/en/>
29. Alzheimer's Association. Lecanemab Approved for Treatment of Early Alzheimer's Disease. <https://www.alz.org/alzheimers-dementia/treatments/lecanemab-legembi>
30. CND Life Sciences. SYN-ONE TEST®. <https://cndlifesciences.com/syn-one-test/>
31. Donadio V, Doppler K, Incensi A, et al. Abnormal alpha-synuclein deposits in skin nerves: intra- and inter-laboratory reproducibility. *Eur J Neurol*. 2019;26(10):1245-1251. doi:10.1111/ene.13939
32. Levine TD, Bellaire B, Gibbons C, Freeman R. Cutaneous alpha-synuclein deposition in postural tachycardia patients. *Ann Clin Transl Neurol*. 2021;8(4):908-917. doi:10.1002/acn3.51347
33. Kim JY, Illigens BM, McCormick MP, Wang N, Gibbons CH. Alpha-Synuclein in Skin Nerve Fibers as a Biomarker for Alpha-Synucleinopathies. *J Clin Neurol*. 2019;15(2):135-142. doi:10.3988/jcn.2019.15.2.135
34. Waqar S, Khan H, Zulfiqar SK, Ahmad A. Skin Biopsy as a Diagnostic Tool for Synucleinopathies. *Cureus*. 2023;15(10):e47179. doi:10.7759/cureus.47179
35. Dage JL, Wennberg AMV, Airey DC, et al. Levels of tau protein in plasma are associated with neurodegeneration and cognitive function in a population-based elderly cohort. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2016;12(12):1226-1234. doi:10.1016/j.jalz.2016.06.001
36. Lewczuk P, Matzen A, Blennow K, et al. Cerebrospinal Fluid Abeta42/40 Corresponds Better than Abeta42 to Amyloid PET in Alzheimer's Disease. *Journal of Alzheimer's disease : JAD*. 2017;55(2):813-822. doi:10.3233/jad-160722
37. Talwar P, Sinha J, Grover S, et al. Meta-analysis of apolipoprotein E levels in the cerebrospinal fluid of patients with Alzheimer's disease. *Journal of the neurological sciences*. 2016;360:179-87. doi:10.1016/j.jns.2015.12.004
38. Wang H, Stewart T, Toledo JB, et al. A Longitudinal Study of Total and Phosphorylated alpha-Synuclein with Other Biomarkers in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment. *Journal of Alzheimer's disease : JAD*. 2018;61(4):1541-1553. doi:10.3233/jad-171013
39. Zhang J, Zhang CH, Li RJ, et al. Accuracy of urinary AD7c-NTP for diagnosing Alzheimer's disease: a systematic review and meta-analysis. *Journal of Alzheimer's disease : JAD*. 2014;40(1):153-9. doi:10.3233/jad-131445
40. Wang S, Kojima K, Mobley JA, West AB. Proteomic analysis of urinary extracellular vesicles reveal biomarkers for neurologic disease. *EBioMedicine*. 2019;45:351-361. doi:10.1016/j.ebiom.2019.06.021
41. Liu Y, Wei M, Yue K, et al. Study on Urine Metabolic Profile of Abeta25-35-Induced Alzheimer's Disease Using UHPLC-Q-TOF-MS. *Neuroscience*. 2018;394:30-43. doi:10.1016/j.neuroscience.2018.10.001
42. Fossati S, Ramos Cejudo J, Debure L, et al. Plasma tau complements CSF tau and P-tau in the diagnosis of Alzheimer's disease. *Alzheimer's & dementia (Amsterdam, Netherlands)*. 2019;11:483-492. doi:10.1016/j.dadm.2019.05.001
43. Tatebe H, Kasai T, Ohmichi T, et al. Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer's disease and down syndrome. *Molecular neurodegeneration*. 2017;12(1):63. doi:10.1186/s13024-017-0206-8
44. Shen XN, Niu LD, Wang YJ, et al. Inflammatory markers in Alzheimer's disease and mild cognitive impairment: a meta-analysis and systematic review of 170 studies. *J Neurol Neurosurg Psychiatry*. 2019;90(5):590-598. doi:10.1136/jnnp-2018-319148
45. Palmqvist S, Janelidze S, Stomrud E, et al. Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related β -Amyloid Status. *JAMA Neurol*. 2019;76(9):1060-9. doi:10.1001/jamaneurol.2019.1632
46. Kim K, Kim M-J, Kim DW, Kim SY, Park S, Park CB. Clinically accurate diagnosis of Alzheimer's disease via multiplexed sensing of core biomarkers in human plasma. *Nature Communications*. 2020;11(1):119. doi:10.1038/s41467-019-13901-z
47. Simrén J, Leuzy A, Karikari TK, et al. The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease. *Alzheimer's & Dementia*. 2021;17(7):1145-1156. doi:10.1002/alz.12283

Reimbursement Policy:

Biochemical Markers of Alzheimer Disease and Dementia - Lab Benefit Program (LBM)

48. Qu Y, Ma YH, Huang YY, et al. Blood biomarkers for the diagnosis of amnesic mild cognitive impairment and Alzheimer's disease: A systematic review and meta-analysis. *Neurosci Biobehav Rev*. 2021;128:479-486. doi:10.1016/j.neubiorev.2021.07.007
49. Chen YR, Liang CS, Chu H, et al. Diagnostic accuracy of blood biomarkers for Alzheimer's disease and amnesic mild cognitive impairment: A meta-analysis. *Ageing Res Rev*. 2021;71:101446. doi:10.1016/j.arr.2021.101446
50. Yoong SQ, Lu J, Xing H, Gyanwali B, Tan YQ, Wu XV. The prognostic utility of CSF neurogranin in predicting future cognitive decline in the Alzheimer's disease continuum: A systematic review and meta-analysis with narrative synthesis. *Ageing Res Rev*. 2021;72:101491. doi:10.1016/j.arr.2021.101491
51. Nojima H, Ito S, Kushida A, et al. Clinical utility of cerebrospinal fluid biomarkers measured by LUMIPULSE® system. *Ann Clin Transl Neurol*. 2022;9(12):1898-1909. doi:10.1002/acn3.51681
52. Schindler SE, Petersen KK, Saef B, et al. Head-to-head comparison of leading blood tests for Alzheimer's disease pathology. *medRxiv*. Jul 3 2024;doi:10.1101/2024.06.12.24308839
53. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2011;7(3):263-9. doi:10.1016/j.jalz.2011.03.005
54. Mattsson N, Andreasson U, Persson S, et al. The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2011;7(4):386-395 e6. doi:10.1016/j.jalz.2011.05.2243
55. Cordell CB, Borson S, Boustani M, et al. Alzheimer's Association recommendations for operationalizing the detection of cognitive impairment during the Medicare Annual Wellness Visit in a primary care setting. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2013;9(2):141-50. doi:10.1016/j.jalz.2012.09.011
56. Shaw LM, Arias J, Blennow K, et al. Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2018;14(11):1505-1521. doi:10.1016/j.jalz.2018.07.220
57. Hansson O, Edelmayer RM, Boxer AL, et al. The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2022;18(12):2669-2686. doi:10.1002/alz.12756
58. Jack CR, Jr., Andrews SJ, Beach TG, et al. Revised criteria for the diagnosis and staging of Alzheimer's disease. *Nat Med*. Aug 2024;30(8):2121-2124. doi:10.1038/s41591-024-02988-7
59. Rabinovici GD, Knopman DS, Arbizu J, et al. Updated Appropriate Use Criteria for Amyloid and Tau PET: A Report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup. *J Nucl Med*. Jun 6 2025;66(Suppl 2):S5-s31. doi:10.2967/jnumed.124.268756
60. Simonsen AH, Herukka SK, Andreasen N, et al. Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2017;13(3):274-284. doi:10.1016/j.jalz.2016.09.008
61. Herukka SK, Simonsen AH, Andreasen N, et al. Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2017;13(3):285-295. doi:10.1016/j.jalz.2016.09.009
62. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2011;7(3):270-9. doi:10.1016/j.jalz.2011.03.008
63. Jack CR, Jr., Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2018;14(4):535-562. doi:10.1016/j.jalz.2018.02.018
64. WHO. Preferred product characteristics of blood-based biomarker diagnostics for Alzheimer disease. <https://www.who.int/publications/i/item/9789240099067>

Reimbursement Policy:

Biochemical Markers of Alzheimer Disease and Dementia - Lab Benefit Program (LBM)

65. GBSC. Biomarker Consortium. Global Biomarker Standardization Consortium (GBSC); Alzheimer's Association. https://www.alz.org/research/for_researchers/partnerships/biomarker_consortium
66. Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology*. 2001;56(9):1143-53. doi:10.1212/wnl.56.9.1143
67. McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. *Neurology*. 2017;89(1):88-100. doi:10.1212/wnl.0000000000004058
68. Lewczuk P, Riederer P, O'Bryant SE, et al. Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. *The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry*. 2018;19(4):244-328. doi:10.1080/15622975.2017.1375556
69. Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. *Lancet Neurol*. 2014;13(6):614-29. doi:10.1016/s1474-4422(14)70090-0
70. Dubois B, Villain N, Frisoni GB, et al. Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. *Lancet Neurol*. 2021;20(6):484-496. doi:10.1016/s1474-4422(21)00066-1
71. Owens DK, Davidson KW, Krist AH, et al. Screening for Cognitive Impairment in Older Adults: US Preventive Services Task Force Recommendation Statement. *Jama*. 2020;323(8):757-763. doi:10.1001/jama.2020.0435
72. Sorbi S, Hort J, Erkinjuntti T, et al. EFNS-ENS Guidelines on the diagnosis and management of disorders associated with dementia. *Eur J Neurol*. 2012;19(9):1159-79. doi:10.1111/j.1468-1331.2012.03784.x
73. Ismail Z, Black SE, Camicioli R, et al. Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2020;16(8):1182-1195. doi:10.1002/alz.12105
74. NICE. Dementia: assessment, management and support for people living with dementia and their carers. <https://www.nice.org.uk/guidance/ng97/chapter/Recommendations>
75. Gottlieb S. Statement from FDA Commissioner Scott Gottlieb, M.D. on advancing the development of novel treatments for neurological conditions; part of broader effort on modernizing FDA's new drug review programs. U.S. Food and Drug Administration. <https://www.americanpharmaceuticalreview.com/1315-News/347185-Statement-from-FDA-Commissioner-on-Advancing-the-Development-of-Novel-Treatments-for-Neurological-Conditions/>
76. FDA. Early Alzheimer's Disease: Developing Drugs for Treatment. U.S. Food and Drug Administration Center for Drug Evaluation and Research Center for Biologics Evaluation and Research. <https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM596728.pdf>
77. FDA. K242706. https://www.accessdata.fda.gov/cdrh_docs/pdf24/K242706.pdf

Reimbursement Policy:

Biochemical Markers of Alzheimer Disease and Dementia - Lab Benefit Program (LBM)

Revision History

Company(ies)	DATE	REVISION
EmblemHealth	10/2025	- Updates with effective date of 2/13/2026: - Coverage Criteria 1 edited to allow p-tau/AB42 and t-tau/AB42 ratio in CSF - New Coverage Criteria 2 to allow p-tau/AB42 ratio measurement in plasma - Former Coverage Criteria 2 and 3, now Coverage Criteria 3 and 4, edited to ensure consistency with the new allowances in Coverage Criteria 1 and 2
EmblemHealth	10/2025	Transferred policy content to individual company-branded template. No changes to policy title or policy number.
EmblemHealth	12/2024	- Following Coding Modifications, effective 1/1/2025: - Added CPT code 82233, 82234, 83884, 84393, 84394 - Removed CPT code 0206U, 0207U, 0289U, 0346U, 0393U, 0412U 0443U, 0445U, 0459U, 0547U, 0551U, 0548U, 0568U, and 0596U
EmblemHealth ConnectiCare	11/2024	- Updates with effective date of 3/15/2025: - Addition of new Coverage Criteria 1 - Former Coverage Criteria 1 updated to Coverage Criteria 2, with removal of amyloid beta peptides from the list of unallowed CSF biomarkers
EmblemHealth	7/2024	Lab Benefit Program (LBM) expanded to include EmblemHealth HMO/ PPO (Non-City) Commercial, Medicare and Medicaid plans effective 10/1/2024
EmblemHealth ConnectiCare	11/2023	- Coverage Criterion 1-3 edited with addition of “or dementia” so that they read “Alzheimer disease or dementia” - Added CPT code 0412U to the Applicable CPT/HCPCS Procedure Codes table with effective date of 10/1/2023 - Added CPT codes 0358U and 0393U to the Applicable CPT/HCPCS Procedure Codes table with effective date of 3/15/2024



Reimbursement Policy:

Biochemical Markers of Alzheimer Disease and Dementia - Lab Benefit Program (LBM)

Company(ies)	DATE	REVISION
EmblemHealth ConnectiCare	11/2022	Reformatted and reorganized policy, transferred content to new template with new Reimbursement Policy Number